<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03009461</url>
  </required_header>
  <id_info>
    <org_study_id>MPVTT</org_study_id>
    <nct_id>NCT03009461</nct_id>
  </id_info>
  <brief_title>Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis</brief_title>
  <official_title>Randomized Trial of Sorafenib Plus Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the Barcelona clinic liver cancer (BCLC) staging treatment guideline, sorafenib
      is recommended for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombosis (PVTT),
      but HCC with major PVTT (in the main trunk or 1st-order branches of the portal vein) did not
      benefit much from sorafenib in previous studies. There is no established standard treatment
      for HCC patients with major PVTT, the investigators conducted a randomized, phase 2 study to
      investigate the survival benefit of sorafenib plus Hepatic arterial infusion chemotherapy
      (HAIC) with Oxaliplatin and Fluorouracil versus sorafenib for Hepatocellular Carcinoma with
      Major Portal Vein Tumor Thrombosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>HepatoCellular Carcinoma</condition>
  <condition>Portal Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Sor-HAIC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sor group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HAIC</intervention_name>
    <description>Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.</description>
    <arm_group_label>Sor-HAIC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.</description>
    <arm_group_label>Sor-HAIC group</arm_group_label>
    <arm_group_label>Sor group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have histologically or clinically confirmed hepatocellular carcinoma.

          -  HCC with major PVTT (in the main trunk or 1st-order branches of the portal vein)

          -  Child A class

          -  Patient's Eastern Cooperative Oncology Group (ECOG) performance status must be =&lt; 2
             (Karnofsky &gt;= 60%)

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Hemoglobin &gt;= 90g/L

          -  Total bilirubin =&lt; 2 X institutional upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])
             =&lt; 2.5 X institutional upper limit of normality

          -  Creatinine =&lt; 1.5 X institutional upper limit of normal

          -  Albumin &gt;= 30g/L

          -  Patient must be able to understand and willing to sign a written informed consent
             document

        Exclusion Criteria:

          -  Patients who have had prior chemotherapy with Oxaliplatin or Fluorouracil or
             sorafenib.

          -  Patient who is receiving any other investigational agents

          -  Patient who have a diagnosis of hepatic encephalopathy

          -  Patients who have a diagnosis of sclerosing cholangitis.

          -  Patients who have a diagnosis of Gilbert's disease.

          -  Patients who have clinical ascites

          -  Patient must not have any uncontrolled concurrent illness including, but not limited
             to, ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, uncontrolled diabetes mellitus and hypertension, or
             psychiatric illness/social situations that would limit compliance with study
             requirements

          -  No other malignancy except localized basal cell or squamous cell skin cancer in the
             past 5 years

          -  Patient who is pregnant or lactating

          -  Patient Allergic to Iodine contrast medium

          -  Uncontrolled severe coagulation disorders (INR &lt; 1.5 in patients not on warfarin
             therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaodong Wang</last_name>
    <phone>+861088196476</phone>
    <email>xiaodongw75@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Wang, MD</last_name>
      <phone>008610-88196476</phone>
      <email>wangxde@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Guang Cao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianhai Guo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haifeng Xu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peng Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jungang Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Xiaodong Wang, MD</investigator_full_name>
    <investigator_title>Chief Physician, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Portal vein tumor thrombosis</keyword>
  <keyword>Hepatic arterial infusion chemotherapy</keyword>
  <keyword>Sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

